Learn from the SARS-CoV-2 nucleic acid test to increase the experience of dealing with the “disease X

RT‒PCR is crucial for screening for epidemic diseases such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, false positives further plague epidemic prevention and control. This study conducted a stratified study on the initial screening Ct values and false positive ratios, p...

Full description

Saved in:
Bibliographic Details
Published inBMC infectious diseases Vol. 25; no. 1; pp. 593 - 9
Main Authors Yang, Xin, Li, Jinming
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 24.04.2025
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract RT‒PCR is crucial for screening for epidemic diseases such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, false positives further plague epidemic prevention and control. This study conducted a stratified study on the initial screening Ct values and false positive ratios, providing experience and reference for addressing future "Disease X". Data from 1,255 positive or suspected positive results were obtained from eleven laboratories with seven different reagents. The proportion of false positives was analyzed on the basis of different Ct values among different reagents and various testing institutions. When the Ct values of both target genes in the initial detection were < 30, a false positive was considered a small probability event (≤ 1.72%). However, when the 30 ≤ Ct value was < 35, significant differences were noted (0%, 1.41%, 7.69%, and 9.14%, P < 0.001). When the Ct value of any target gene is > 35, 15.58 - 24.22% of positive results may be false positive. Among the suspected positive samples, 53.23% were false positive according to retesting. After separate sampling, 4 tubes (30 people involved) from 19 tubes (133 people involved) were negative. In summary, different strategies should be adopted according to the different Ct values of primary screening results under pandemic prevention and control conditions, which may provide a better reference for the rapid diagnosis of the next "Disease X".
AbstractList RT‒PCR is crucial for screening for epidemic diseases such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, false positives further plague epidemic prevention and control. This study conducted a stratified study on the initial screening Ct values and false positive ratios, providing experience and reference for addressing future "Disease X". Data from 1,255 positive or suspected positive results were obtained from eleven laboratories with seven different reagents. The proportion of false positives was analyzed on the basis of different Ct values among different reagents and various testing institutions. When the Ct values of both target genes in the initial detection were < 30, a false positive was considered a small probability event (≤ 1.72%). However, when the 30 ≤ Ct value was < 35, significant differences were noted (0%, 1.41%, 7.69%, and 9.14%, P < 0.001). When the Ct value of any target gene is > 35, 15.58 - 24.22% of positive results may be false positive. Among the suspected positive samples, 53.23% were false positive according to retesting. After separate sampling, 4 tubes (30 people involved) from 19 tubes (133 people involved) were negative. In summary, different strategies should be adopted according to the different Ct values of primary screening results under pandemic prevention and control conditions, which may provide a better reference for the rapid diagnosis of the next "Disease X".
BackgroundRT‒PCR is crucial for screening for epidemic diseases such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, false positives further plague epidemic prevention and control. This study conducted a stratified study on the initial screening Ct values and false positive ratios, providing experience and reference for addressing future “Disease X”.MethodsData from 1,255 positive or suspected positive results were obtained from eleven laboratories with seven different reagents. The proportion of false positives was analyzed on the basis of different Ct values among different reagents and various testing institutions.ResultsWhen the Ct values of both target genes in the initial detection were < 30, a false positive was considered a small probability event (≤ 1.72%). However, when the 30 ≤ Ct value was < 35, significant differences were noted (0%, 1.41%, 7.69%, and 9.14%, P < 0.001). When the Ct value of any target gene is > 35, 15.58 − 24.22% of positive results may be false positive. Among the suspected positive samples, 53.23% were false positive according to retesting. After separate sampling, 4 tubes (30 people involved) from 19 tubes (133 people involved) were negative.ConclusionsIn summary, different strategies should be adopted according to the different Ct values of primary screening results under pandemic prevention and control conditions, which may provide a better reference for the rapid diagnosis of the next “Disease X”.
RT-PCR is crucial for screening for epidemic diseases such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, false positives further plague epidemic prevention and control. This study conducted a stratified study on the initial screening Ct values and false positive ratios, providing experience and reference for addressing future "Disease X". Data from 1,255 positive or suspected positive results were obtained from eleven laboratories with seven different reagents. The proportion of false positives was analyzed on the basis of different Ct values among different reagents and various testing institutions. When the Ct values of both target genes in the initial detection were < 30, a false positive was considered a small probability event ([less than or equal to] 1.72%). However, when the 30 [less than or equal to] Ct value was < 35, significant differences were noted (0%, 1.41%, 7.69%, and 9.14%, P < 0.001). When the Ct value of any target gene is > 35, 15.58 - 24.22% of positive results may be false positive. Among the suspected positive samples, 53.23% were false positive according to retesting. After separate sampling, 4 tubes (30 people involved) from 19 tubes (133 people involved) were negative. In summary, different strategies should be adopted according to the different Ct values of primary screening results under pandemic prevention and control conditions, which may provide a better reference for the rapid diagnosis of the next "Disease X".
Background RT-PCR is crucial for screening for epidemic diseases such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, false positives further plague epidemic prevention and control. This study conducted a stratified study on the initial screening Ct values and false positive ratios, providing experience and reference for addressing future "Disease X". Methods Data from 1,255 positive or suspected positive results were obtained from eleven laboratories with seven different reagents. The proportion of false positives was analyzed on the basis of different Ct values among different reagents and various testing institutions. Results When the Ct values of both target genes in the initial detection were < 30, a false positive was considered a small probability event ([less than or equal to] 1.72%). However, when the 30 [less than or equal to] Ct value was < 35, significant differences were noted (0%, 1.41%, 7.69%, and 9.14%, P < 0.001). When the Ct value of any target gene is > 35, 15.58 - 24.22% of positive results may be false positive. Among the suspected positive samples, 53.23% were false positive according to retesting. After separate sampling, 4 tubes (30 people involved) from 19 tubes (133 people involved) were negative. Conclusions In summary, different strategies should be adopted according to the different Ct values of primary screening results under pandemic prevention and control conditions, which may provide a better reference for the rapid diagnosis of the next "Disease X". Keywords: Retest, False positive, RT-PCR, COVID-19, SARS-CoV-2, Cycle threshold, Disease X
Abstract Background RT‒PCR is crucial for screening for epidemic diseases such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, false positives further plague epidemic prevention and control. This study conducted a stratified study on the initial screening Ct values and false positive ratios, providing experience and reference for addressing future “Disease X”. Methods Data from 1,255 positive or suspected positive results were obtained from eleven laboratories with seven different reagents. The proportion of false positives was analyzed on the basis of different Ct values among different reagents and various testing institutions. Results When the Ct values of both target genes in the initial detection were < 30, a false positive was considered a small probability event (≤ 1.72%). However, when the 30 ≤ Ct value was < 35, significant differences were noted (0%, 1.41%, 7.69%, and 9.14%, P < 0.001). When the Ct value of any target gene is > 35, 15.58 − 24.22% of positive results may be false positive. Among the suspected positive samples, 53.23% were false positive according to retesting. After separate sampling, 4 tubes (30 people involved) from 19 tubes (133 people involved) were negative. Conclusions In summary, different strategies should be adopted according to the different Ct values of primary screening results under pandemic prevention and control conditions, which may provide a better reference for the rapid diagnosis of the next “Disease X”.
RT‒PCR is crucial for screening for epidemic diseases such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, false positives further plague epidemic prevention and control. This study conducted a stratified study on the initial screening Ct values and false positive ratios, providing experience and reference for addressing future "Disease X".BACKGROUNDRT‒PCR is crucial for screening for epidemic diseases such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, false positives further plague epidemic prevention and control. This study conducted a stratified study on the initial screening Ct values and false positive ratios, providing experience and reference for addressing future "Disease X".Data from 1,255 positive or suspected positive results were obtained from eleven laboratories with seven different reagents. The proportion of false positives was analyzed on the basis of different Ct values among different reagents and various testing institutions.METHODSData from 1,255 positive or suspected positive results were obtained from eleven laboratories with seven different reagents. The proportion of false positives was analyzed on the basis of different Ct values among different reagents and various testing institutions.When the Ct values of both target genes in the initial detection were < 30, a false positive was considered a small probability event (≤ 1.72%). However, when the 30 ≤ Ct value was < 35, significant differences were noted (0%, 1.41%, 7.69%, and 9.14%, P < 0.001). When the Ct value of any target gene is > 35, 15.58 - 24.22% of positive results may be false positive. Among the suspected positive samples, 53.23% were false positive according to retesting. After separate sampling, 4 tubes (30 people involved) from 19 tubes (133 people involved) were negative.RESULTSWhen the Ct values of both target genes in the initial detection were < 30, a false positive was considered a small probability event (≤ 1.72%). However, when the 30 ≤ Ct value was < 35, significant differences were noted (0%, 1.41%, 7.69%, and 9.14%, P < 0.001). When the Ct value of any target gene is > 35, 15.58 - 24.22% of positive results may be false positive. Among the suspected positive samples, 53.23% were false positive according to retesting. After separate sampling, 4 tubes (30 people involved) from 19 tubes (133 people involved) were negative.In summary, different strategies should be adopted according to the different Ct values of primary screening results under pandemic prevention and control conditions, which may provide a better reference for the rapid diagnosis of the next "Disease X".CONCLUSIONSIn summary, different strategies should be adopted according to the different Ct values of primary screening results under pandemic prevention and control conditions, which may provide a better reference for the rapid diagnosis of the next "Disease X".
ArticleNumber 593
Audience Academic
Author Yang, Xin
Li, Jinming
Author_xml – sequence: 1
  givenname: Xin
  surname: Yang
  fullname: Yang, Xin
– sequence: 2
  givenname: Jinming
  surname: Li
  fullname: Li, Jinming
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40275167$$D View this record in MEDLINE/PubMed
BookMark eNqNks1uEzEQx1eoiH7AC3BAlrjAYYs_1uvdE4oiCpEiVWqg4mZ5veONo40d7F1obzwIT8eT4CSlNIgDmoOtmZ__oxn_T7Mj5x1k2XOCzwmpyjeR0ErUOaY8J7iuSS4eZSekECSnjBVHD-7H2WmMK4yJqGj9JDsuMBWclOIk6-aggkMm-DUaloAWk6tFPvXXOUVu1D1YjZS2LRogDmjwyDodQEXYwXCzgWDBaUDeoBZUb12HvtlhuSv__P6jtXFHf36aPTaqj_Ds7jzLPl28-zj9kM8v38-mk3muecWHvCxwrVXZ1mVjDAZNOJCmaRWBirdtsS0wzKs0EnBdGqFqUhNGNRAQvBHAzrLZXrf1aiU3wa5VuJVeWblL-NBJFQabJpO1FsI0GJeUqaRcVg3TGJqKGQ7b7knr7V5rMzZraDW4Iaj-QPSw4uxSdv6rJBSnEDQpvLpTCP7LmFYo1zZq6HvlwI9RMlIXJafpVxL68i905cfg0q4ko5hwSktc_6E6lSawzvjUWG9F5aRighAhaJGo839QKVpYW51MZGzKHzx4ffAgMQPcDJ0aY5SzxdX_s5fXh-yLhxu8X91v_yWA7gEdfIwBzD1CsNyaXO5NLpPJ5c7kUrBfVYnrSw
Cites_doi 10.3201/eid2608.201843
10.1101/2020.04.26.20080911
10.3390/diseases11010020
10.1016/j.jhazmat.2024.134201
10.1080/14787210.2022.2089653
10.1016/S1473-3099(21)00146-8
10.1097/JOM.0000000000002138
10.3390/v12060582
10.1016/S2213-2600(20)30453-7
10.1002/anie.202400413
10.1016/j.jmii.2020.02.012
10.1016/j.cmi.2020.10.003
10.1093/ofid/ofab453
10.1093/clinchem/hvaa214
10.1080/17476348.2021.1917389
10.1183/13993003.00360-2021
10.2807/1560-7917.ES.2020.25.50.2000568
10.1128/cmr.00072-23
10.1080/14737159.2020.1757437
10.1080/17476348.2022.2049760
10.3389/fpubh.2023.1240308
10.1016/j.jmoldx.2020.10.008
ContentType Journal Article
Copyright 2025. The Author(s).
COPYRIGHT 2025 BioMed Central Ltd.
2025. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2025 2025
Copyright_xml – notice: 2025. The Author(s).
– notice: COPYRIGHT 2025 BioMed Central Ltd.
– notice: 2025. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2025 2025
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
IOV
ISR
3V.
7QL
7T2
7U9
7X7
7XB
88E
8C1
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BENPR
C1K
CCPQU
COVID
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
M7N
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12879-025-10991-7
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Opposing Viewpoints (Gale in Context)
Gale In Context: Science
ProQuest Central (Corporate)
Bacteriology Abstracts (Microbiology B)
Health and Safety Science Abstracts (Full archive)
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Public Health Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
Environmental Sciences and Pollution Management
ProQuest One Community College
Coronavirus Research Database
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
Algology Mycology and Protozoology Abstracts (Microbiology C)
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest Central
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
Health & Safety Science Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Public Health
Virology and AIDS Abstracts
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE
Publicly Available Content Database





MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1471-2334
EndPage 9
ExternalDocumentID oai_doaj_org_article_9c77fb00623a46d68b3c0eb83f5ebff0
PMC12020272
A837117724
40275167
10_1186_s12879_025_10991_7
Genre Journal Article
GeographicLocations China
Israel
Shanghai China
GeographicLocations_xml – name: China
– name: Israel
– name: Shanghai China
GroupedDBID ---
0R~
23N
2WC
53G
5VS
6J9
6PF
7X7
88E
8C1
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AEUYN
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
IOV
ISR
ITC
KQ8
M1P
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PMFND
3V.
7QL
7T2
7U9
7XB
8FK
AZQEC
C1K
COVID
DWQXO
H94
K9.
M48
M7N
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c585t-6409ca6d96bff0ec15e1bbda1e85dd46d963058334e5c6f7a919132ce1e75b7e3
IEDL.DBID 7X7
ISSN 1471-2334
IngestDate Wed Aug 27 01:24:17 EDT 2025
Thu Aug 21 18:26:54 EDT 2025
Fri Jul 11 18:30:14 EDT 2025
Fri Jul 25 09:19:51 EDT 2025
Tue Jun 17 21:59:21 EDT 2025
Tue Jun 10 20:58:12 EDT 2025
Fri Jun 27 05:13:20 EDT 2025
Fri Jun 27 05:11:48 EDT 2025
Mon Jul 21 05:45:19 EDT 2025
Tue Jul 01 05:03:23 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords COVID‒19
False positive
Retest
Cycle threshold
RT‒PCR
Disease X
SARS‒CoV‒2
Language English
License 2025. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c585t-6409ca6d96bff0ec15e1bbda1e85dd46d963058334e5c6f7a919132ce1e75b7e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://www.proquest.com/docview/3201522609?pq-origsite=%requestingapplication%
PMID 40275167
PQID 3201522609
PQPubID 42582
PageCount 9
ParticipantIDs doaj_primary_oai_doaj_org_article_9c77fb00623a46d68b3c0eb83f5ebff0
pubmedcentral_primary_oai_pubmedcentral_nih_gov_12020272
proquest_miscellaneous_3194652782
proquest_journals_3201522609
gale_infotracmisc_A837117724
gale_infotracacademiconefile_A837117724
gale_incontextgauss_ISR_A837117724
gale_incontextgauss_IOV_A837117724
pubmed_primary_40275167
crossref_primary_10_1186_s12879_025_10991_7
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2025-04-24
PublicationDateYYYYMMDD 2025-04-24
PublicationDate_xml – month: 04
  year: 2025
  text: 2025-04-24
  day: 24
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle BMC infectious diseases
PublicationTitleAlternate BMC Infect Dis
PublicationYear 2025
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References 10991_CR2
DS Mouliou (10991_CR19) 2022; 16
10991_CR18
X Li (10991_CR20) 2024; 470
CC Lai (10991_CR7) 2020; 53
GD Braunstein (10991_CR10) 2021; 63
E Surkova (10991_CR15) 2020; 8
10991_CR9
DS Mouliou (10991_CR17) 2022; 20
JP Skittrall (10991_CR11) 2021; 27
M Marando (10991_CR1) 2020; 7
Y Galipeau (10991_CR5) 2023; 11
R Mogling (10991_CR13) 2020; 26
JF Huggett (10991_CR14) 2020; 66
NNY Tsang (10991_CR3) 2021; 21
P Sen (10991_CR6) 2024; 63
10991_CR21
Z Wang (10991_CR23) 2021; 23
A Tahamtan (10991_CR4) 2020; 20
VP Shah (10991_CR8) 2021; 8
10991_CR12
10991_CR22
DS Mouliou (10991_CR16) 2021; 15
References_xml – volume: 26
  start-page: 1944
  issue: 8
  year: 2020
  ident: 10991_CR13
  publication-title: Emerg Infect Dis
  doi: 10.3201/eid2608.201843
– ident: 10991_CR12
  doi: 10.1101/2020.04.26.20080911
– ident: 10991_CR18
  doi: 10.3390/diseases11010020
– volume: 470
  start-page: 134201
  year: 2024
  ident: 10991_CR20
  publication-title: J Hazard Mater
  doi: 10.1016/j.jhazmat.2024.134201
– volume: 7
  start-page: 001680
  issue: 7
  year: 2020
  ident: 10991_CR1
  publication-title: Eur J Case Rep Intern Med
– volume: 20
  start-page: 1163
  issue: 9
  year: 2022
  ident: 10991_CR17
  publication-title: Expert Rev anti-infective Therapy
  doi: 10.1080/14787210.2022.2089653
– volume: 21
  start-page: 1233
  issue: 9
  year: 2021
  ident: 10991_CR3
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(21)00146-8
– volume: 63
  start-page: e159
  issue: 3
  year: 2021
  ident: 10991_CR10
  publication-title: J Occup Environ Med
  doi: 10.1097/JOM.0000000000002138
– ident: 10991_CR2
  doi: 10.3390/v12060582
– volume: 8
  start-page: 1167
  issue: 12
  year: 2020
  ident: 10991_CR15
  publication-title: Lancet Respir Med
  doi: 10.1016/S2213-2600(20)30453-7
– volume: 63
  start-page: e202400413
  issue: 20
  year: 2024
  ident: 10991_CR6
  publication-title: Angewandte Chemie (International Ed English)
  doi: 10.1002/anie.202400413
– volume: 53
  start-page: 404
  issue: 3
  year: 2020
  ident: 10991_CR7
  publication-title: J Microbiol Immunol Infect
  doi: 10.1016/j.jmii.2020.02.012
– volume: 27
  start-page: 469
  issue: 3
  year: 2021
  ident: 10991_CR11
  publication-title: Clin Microbiol Infect
  doi: 10.1016/j.cmi.2020.10.003
– volume: 8
  start-page: ofab453
  issue: 9
  year: 2021
  ident: 10991_CR8
  publication-title: Open Forum Infect Dis
  doi: 10.1093/ofid/ofab453
– volume: 66
  start-page: 1369
  issue: 11
  year: 2020
  ident: 10991_CR14
  publication-title: Clin Chem
  doi: 10.1093/clinchem/hvaa214
– volume: 15
  start-page: 993
  issue: 8
  year: 2021
  ident: 10991_CR16
  publication-title: Expert Rev Respir Med
  doi: 10.1080/17476348.2021.1917389
– ident: 10991_CR9
  doi: 10.1183/13993003.00360-2021
– ident: 10991_CR22
  doi: 10.2807/1560-7917.ES.2020.25.50.2000568
– ident: 10991_CR21
  doi: 10.1128/cmr.00072-23
– volume: 20
  start-page: 453
  issue: 5
  year: 2020
  ident: 10991_CR4
  publication-title: Expert Rev Mol Diagn
  doi: 10.1080/14737159.2020.1757437
– volume: 16
  start-page: 263
  issue: 3
  year: 2022
  ident: 10991_CR19
  publication-title: Expert Rev Respir Med
  doi: 10.1080/17476348.2022.2049760
– volume: 11
  start-page: 1240308
  year: 2023
  ident: 10991_CR5
  publication-title: Front Public Health
  doi: 10.3389/fpubh.2023.1240308
– volume: 23
  start-page: 19
  issue: 1
  year: 2021
  ident: 10991_CR23
  publication-title: J Mol Diagn
  doi: 10.1016/j.jmoldx.2020.10.008
SSID ssj0017829
Score 2.4205372
Snippet RT‒PCR is crucial for screening for epidemic diseases such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, false positives further...
RT-PCR is crucial for screening for epidemic diseases such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, false positives further...
Background RT-PCR is crucial for screening for epidemic diseases such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, false positives...
BackgroundRT‒PCR is crucial for screening for epidemic diseases such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, false positives...
Abstract Background RT‒PCR is crucial for screening for epidemic diseases such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, false...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 593
SubjectTerms Acids
Chemical tests and reagents
Chi-square test
China
Coronaviruses
COVID-19
COVID-19 - diagnosis
COVID-19 Nucleic Acid Testing - methods
Cycle threshold
Data collection
Disease control
Disease prevention
Diseases
Epidemics
False positive
False Positive Reactions
Gene amplification
Genes
Health aspects
Humans
Israel
Laboratories
Medical screening
Nucleic acids
Pandemics
Polymerase chain reaction
Quality control
Reagents
Respiratory diseases
Retest
RT‒PCR
SARS-CoV-2 - genetics
SARS-CoV-2 - isolation & purification
SARS‒CoV‒2
Sensitivity and Specificity
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Synthesis
Testing
Tubes
Viral diseases
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQD4gLovwGCjIIiQOymjiOHR-XiqogFaQurfZm-S_tXhJEsvc-CE_HkzDjZFcbIcSFa2YiJTNjzzce-zMhb73KdePqgvkgBBPcB6aj10xFvAwp5MpZPDt8_kWeXYrPq2q1d9UX7gkb6YFHwx1rr1SDscFLK2SQtSt9Hl1dNlV0TZOqdch522Jq6h9A3tPbIzK1PO5hFlaa4dWt2AkqmJqlocTW_-ecvJeU5hsm9zLQ6QNyf4KOdDF-8iG5E9uH5O751Bx_RK4TVyrFAyMUYB1dLi6W7KS7Ypy2yFq89tT6daAALgc6dHTdImLsY1KOO8pj2jU0AHyEnEZxlTaJf93-nFo5dPWYXJ5-_HZyxqZ7FJiHYmBgEmo4b2XQEg0WfVHFwrlgi1hXIQgUwKivy1LEystGWQ1FXMl9LKKqnIrlE3LQdm18RiiohTLkLtc8ANSzugqAH6rIZY2PRUbeb81qvo90GSaVGbU0oxMMOMEkJxiVkQ9o-Z0mUl2nBxAAZgoA868AyMgb9JtBMosWd8tc203fm09fr8wCqm9sSnPxN6XlxUzp3aTUdOBmb6cTCvDrSJI10zyaacKQ9HPxNobMNCX0pgSohWA31xl5vRPjm7jNrY3dBnQKLWTFIXoz8nQMuZ1xBDaYCwlGq2fBOLPeXNKubxJheMFzXOPiz_-HvV-QexwHUi4YF0fkYPixiS8BmA3uVRqDvwHVXjSl
  priority: 102
  providerName: Directory of Open Access Journals
Title Learn from the SARS-CoV-2 nucleic acid test to increase the experience of dealing with the “disease X
URI https://www.ncbi.nlm.nih.gov/pubmed/40275167
https://www.proquest.com/docview/3201522609
https://www.proquest.com/docview/3194652782
https://pubmed.ncbi.nlm.nih.gov/PMC12020272
https://doaj.org/article/9c77fb00623a46d68b3c0eb83f5ebff0
Volume 25
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1Nb9Mw1IJNQlwQ33SMyiAkDsha7Dh2fEJttWkgbaCWTRUXK7Gd0ksylva-H8Kv45fwnpuWRQguOdgvUvK-P-z3CHnrdGKqMufMeSmZFM4zE5xhOuAwJJ_ossC7w2fn6vRCfppn8y7h1nbHKrc6MSpq3zjMkR-lYKnQV0jMh6sfDKdGYXW1G6Fxl-xj6zLkaj3fBVwcrJ_ZXpTJ1VELulgbhgNcsR7Eme4Zo9iz_2_NfMs09Y9N3rJDJw_Jg86BpKMNxR-RO6F-TO6ddSXyJ2QRO6ZSvDZCwbmjs9F0xibNJRO0xt7FS0cLt_QUXMwVXTV0WaPf2IYIHHaNj2lTUQ9OJFg2irnauP3r5mdX0KHzp-Ti5Pjr5JR10xSYg5BgxRREcq5Q3qiyqpLgeBZ4WfqChzzzXuIGyH6epjJkTlW6MBDKpcIFHnRW6pA-I3t1U4cXhAKYT31SJkZ4cPgKk3nwIrIgVI7LckDeb9FqrzZNM2wMNnJlN0SwQAQbiWD1gIwR8ztIbHgdF5rrhe3kxxqndYUqQqQFfKvKy9QloczTKgv4PwPyBulmsaVFjWdmFsW6be3Hz5d2BDE4lqaF_BfQbNoDetcBVQ2Q2RXdPQX4dWyV1YM87EGCYLr-9paHbKcYWvuHjQfk9W4b38TDbnVo1gDDjVSZAO4dkOcbltshR2KZmStAWt5jxh72-jv18ntsG85FgpkucfD_73pJ7gsUkUQyIQ_J3up6HV6B47Uqh1G64JlP-JDsj4_Pv0yHMYkBz-n422-rxy-k
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR1Nb9Mw1BpDAi6IbzoGGATigKwljmPHB4RKYWrZOqR1m3ozie10vSRjaYW48UP4DfwofgnvpUlZhOC2a95rlbxv-30R8sKqQOdZEjLrhGCCW8e0t5opj8uQXKCyFHuHxwdyeCw-TuPpBvnZ9sJgWWVrE2tD7UqLd-Q7EXgqjBUC_fbsC8OtUZhdbVdorMRiz3_7Cke26s3oPfD3Jee7H44GQ9ZsFWAWQuMFk3Cisal0WmZ5Hngbxj7MMpeGPomdEwgAHUiiSPjYylylGo40Ebc-9CrOlI_gf6-QqyIC1cTO9MG6pCQEb6vbxpxE7lRg-5VmuDAW808hUx3nV-8I-NsTXHCF3TLNC35v9xa52QSstL-SsNtkwxd3yLVxk5K_S2b1hFaKbSoUgkk66R9O2KA8YZwWOCt5bmlq545CSLugi5LOC4xTK18j-_WgZVrm1EHQCp6U4t1wDf71_UeTQKLTe-T4Uuh8n2wWZeEfEgpoLnJBFmjuIMBMdewgaok9lwk-Fj3yuiWrOVsN6TD14SaRZsUEA0wwNROM6pF3SPk1Jg7Yrh-U5zPT6KvRVqkcTRKPUnhXmWSRDXyWRHns8Xt65DnyzeAIjQJrdGbpsqrM6NOJ6cOZH1PhXPwLaXLYQXrVIOUlsNmmTV8EfDqO5upgbncwwRDYLriVIdMYosr8UZseebYG4y-xuK7w5RJwQi1kzEF6e-TBSuTWxBGY1g4lEC3pCGOHel1IMT-tx5SHPMCbNb71__d6Sq4Pj8b7Zn90sPeI3OCoLoFgXGyTzcX50j-GoG-RPak1jZLPl63avwGmCWiM
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Learn+from+the+SARS-CoV-2+nucleic+acid+test+to+increase+the+experience+of+dealing+with+the+%E2%80%9Cdisease+X&rft.jtitle=BMC+infectious+diseases&rft.au=Yang%2C+Xin&rft.au=Li%2C+Jinming&rft.date=2025-04-24&rft.pub=BioMed+Central&rft.eissn=1471-2334&rft.volume=25&rft.spage=1&rft_id=info:doi/10.1186%2Fs12879-025-10991-7
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2334&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2334&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2334&client=summon